VETO Stock Overview
A veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for VETO from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Vetoquinol SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €76.70 |
| 52 Week High | €110.00 |
| 52 Week Low | €76.20 |
| Beta | 0.94 |
| 1 Month Change | -6.58% |
| 3 Month Change | -7.37% |
| 1 Year Change | -23.91% |
| 3 Year Change | -41.63% |
| 5 Year Change | 19.84% |
| Change since IPO | 233.48% |
Recent News & Updates
What Vetoquinol SA's (EPA:VETO) P/E Is Not Telling You
Nov 21
Subdued Growth No Barrier To Vetoquinol SA's (EPA:VETO) Price
Aug 06Vetoquinol (EPA:VETO) Ticks All The Boxes When It Comes To Earnings Growth
Jul 13An Intrinsic Calculation For Vetoquinol SA (EPA:VETO) Suggests It's 40% Undervalued
Jun 15Why We're Not Concerned About Vetoquinol SA's (EPA:VETO) Share Price
May 01Recent updates
What Vetoquinol SA's (EPA:VETO) P/E Is Not Telling You
Nov 21Subdued Growth No Barrier To Vetoquinol SA's (EPA:VETO) Price
Aug 06Vetoquinol (EPA:VETO) Ticks All The Boxes When It Comes To Earnings Growth
Jul 13An Intrinsic Calculation For Vetoquinol SA (EPA:VETO) Suggests It's 40% Undervalued
Jun 15Why We're Not Concerned About Vetoquinol SA's (EPA:VETO) Share Price
May 01Here's What Analysts Are Forecasting For Vetoquinol SA (EPA:VETO) After Its Annual Results
Mar 24With EPS Growth And More, Vetoquinol (EPA:VETO) Makes An Interesting Case
Jan 13Vetoquinol SA (EPA:VETO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Dec 19Vetoquinol (EPA:VETO) Seems To Use Debt Quite Sensibly
Nov 23Here's Why We Think Vetoquinol (EPA:VETO) Is Well Worth Watching
Oct 06Is Vetoquinol SA (EPA:VETO) Trading At A 45% Discount?
Sep 12Are Investors Undervaluing Vetoquinol SA (EPA:VETO) By 28%?
May 24Is Vetoquinol (EPA:VETO) Using Too Much Debt?
May 03Vetoquinol SA (EPA:VETO) Shares Could Be 22% Below Their Intrinsic Value Estimate
Jan 05Here's Why Vetoquinol (EPA:VETO) Has Caught The Eye Of Investors
Dec 01We Think Vetoquinol (EPA:VETO) Can Stay On Top Of Its Debt
Oct 07Vetoquinol SA (EPA:VETO) Shares Could Be 31% Below Their Intrinsic Value Estimate
Aug 19Do Vetoquinol's (EPA:VETO) Earnings Warrant Your Attention?
Jul 16Vetoquinol SA (EPA:VETO) Shares Could Be 29% Below Their Intrinsic Value Estimate
May 07I Ran A Stock Scan For Earnings Growth And Vetoquinol (EPA:VETO) Passed With Ease
Apr 06Calculating The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Dec 21Is Vetoquinol (EPA:VETO) Using Too Much Debt?
Nov 29Estimating The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Sep 10Is Vetoquinol (EPA:VETO) A Risky Investment?
Aug 01Is Vetoquinol SA (EPA:VETO) Trading At A 35% Discount?
May 12Vetoquinol SA's (EPA:VETO) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Feb 11A Look At The Intrinsic Value Of Vetoquinol SA (EPA:VETO)
Jan 20Vetoquinol (EPA:VETO) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Dec 29How Much Is Vetoquinol SA (EPA:VETO) Paying Its CEO?
Dec 09We Think Vetoquinol's (EPA:VETO) Statutory Profit Might Understate Its Earnings Potential
Nov 18
Shareholder Returns
| VETO | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -1.3% | -0.1% | -0.4% |
| 1Y | -23.9% | 2.3% | -4.1% |
Return vs Industry: VETO underperformed the French Pharmaceuticals industry which returned 2.3% over the past year.
Return vs Market: VETO underperformed the French Market which returned -4.1% over the past year.
Price Volatility
| VETO volatility | |
|---|---|
| VETO Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: VETO has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: VETO's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 2,519 | Matthieu Frechin | www.vetoquinol.com |
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France.
Vetoquinol SA Fundamentals Summary
| VETO fundamental statistics | |
|---|---|
| Market cap | €901.64m |
| Earnings (TTM) | €47.14m |
| Revenue (TTM) | €537.47m |
19.3x
P/E Ratio1.7x
P/S RatioIs VETO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VETO income statement (TTM) | |
|---|---|
| Revenue | €537.47m |
| Cost of Revenue | €250.03m |
| Gross Profit | €287.44m |
| Other Expenses | €240.30m |
| Earnings | €47.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.98 |
| Gross Margin | 53.48% |
| Net Profit Margin | 8.77% |
| Debt/Equity Ratio | 1.2% |
How did VETO perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield21%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 20:47 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vetoquinol SA is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carole Rozen | CA Cheuvreux |
| Arnaud Cadart | CIC Market Solutions (ESN) |
| Alexandre Letz | Gilbert Dupont |